Paloma Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://palomapharma.com
Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
Phase 1
Completed
- Conditions
- Age-Related Macular Degeneration
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2012-09-24
- Lead Sponsor
- Paloma Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT01033721
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath